- Home
- MDJH vs TENX Comparison
MDJH vs TENX Comparison
Compare MDJH & TENX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MDJH
- TENX
- Stock Information
- Founded
- MDJH 2002
- TENX 1967
- Country
- MDJH United Kingdom
- TENX United States
- Employees
- MDJH N/A
- TENX N/A
- Industry
- MDJH Real Estate
- TENX Biotechnology: Pharmaceutical Preparations
- Sector
- MDJH Finance
- TENX Health Care
- Exchange
- MDJH Nasdaq
- TENX Nasdaq
- Market Cap
- MDJH 13.6M
- TENX 11.4M
- IPO Year
- MDJH 2019
- TENX N/A
- Fundamental
- Price
- MDJH $0.56
- TENX $3.42
- Analyst Decision
- MDJH
- TENX Strong Buy
- Analyst Count
- MDJH 0
- TENX 2
- Target Price
- MDJH N/A
- TENX $30.00
- AVG Volume (30 Days)
- MDJH 48.1K
- TENX 25.5K
- Earning Date
- MDJH 01-01-0001
- TENX 11-11-2024
- Dividend Yield
- MDJH N/A
- TENX N/A
- EPS Growth
- MDJH N/A
- TENX N/A
- EPS
- MDJH N/A
- TENX N/A
- Revenue
- MDJH $114,849.00
- TENX N/A
- Revenue This Year
- MDJH N/A
- TENX N/A
- Revenue Next Year
- MDJH N/A
- TENX N/A
- P/E Ratio
- MDJH N/A
- TENX N/A
- Revenue Growth
- MDJH 289.97
- TENX N/A
- 52 Week Low
- MDJH $0.53
- TENX $2.77
- 52 Week High
- MDJH $2.19
- TENX $61.20
- Technical
- Relative Strength Index (RSI)
- MDJH 28.02
- TENX 44.57
- Support Level
- MDJH $0.62
- TENX $3.28
- Resistance Level
- MDJH $0.68
- TENX $3.50
- Average True Range (ATR)
- MDJH 0.06
- TENX 0.20
- MACD
- MDJH 0.01
- TENX 0.01
- Stochastic Oscillator
- MDJH 9.46
- TENX 32.44
About MDJH MDJM LTD
MDJM Ltd is a real estate service company. The company provides real estate agency services to real estate developer clients, as well as real estate consulting services and independent training services on an as-needed basis. It offers consulting, marketing planning, advertising services, and sales strategies to real estate clients. The company income is derived from commission-based services and minimal consulting and other services. The company has two operating segments; the real estate agent services segment and the hospitality business segment. It derives a majority of its revenue from the People's Republic of China.
About TENX Tenax Therapeutics Inc.
Tenax Therapeutics Inc is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The company owns North American rights to develop and commercialize levosimendan and has released topline data regarding the Phase 2 clinical trial for the use of levosimendan in the treatment of pulmonary hypertension associated with Heart Failure and preserved Ejection Fraction.